drugset / Trial / NCT01613586

A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)

NCT01613586

Phase 2 Completed 287 enrolled Astellas Pharma Europe B.V.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

In this study several dose levels of ASP3652, given orally for 12 weeks, will be compared with placebo in the treatment of female patients with Bladder Pain Syndrome / Interstitial Cystitis.

Timeline

Start
2012-05-31
Primary completion
2014-03-18
Completion
2014-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject ASP3652 Unknown 50 mg Oral
Subject ASP3652 Unknown 150 mg Oral
Subject ASP3652 Unknown 300 mg Oral

Indications